Pharmacokinetic Study of MIN-101 in Healthy Subjects
NCT02232529
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
MIN-101
DRUG:
Placebo
Sponsor
Minerva Neurosciences